HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer

Tamoxifen is a commonly used drug to treat estrogen receptor-positive patients with breast cancer. Despite the outstanding efficacy of tamoxifen, approximately one-third of patients develop resistance toward it, thereby presenting a therapeutic challenge. HOX genes may be involved in the acquisition...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Clara Yuri, Kim, Yu Cheon, Oh, Ji Hoon, Kim, Myoung Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210559/
https://www.ncbi.nlm.nih.gov/pubmed/34149926
http://dx.doi.org/10.7150/jca.59740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210559/
https://www.ncbi.nlm.nih.gov/pubmed/34149926
http://dx.doi.org/10.7150/jca.59740

Ejemplares similares